GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tetraphase Pharmaceuticals Inc (NAS:TTPH) » Definitions » E10

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) E10 : $-41.17 (As of Mar. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Tetraphase Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Tetraphase Pharmaceuticals's adjusted earnings per share data for the fiscal year that ended in Dec. 2019 was $-22.850. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-41.17 for the trailing ten years ended in Dec. 2019.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-05), Tetraphase Pharmaceuticals's current stock price is $ 2.20. Tetraphase Pharmaceuticals's E10 for the fiscal year that ended in Dec. 2019 was $-41.17. Tetraphase Pharmaceuticals's Shiller PE Ratio of today is .


Tetraphase Pharmaceuticals E10 Historical Data

The historical data trend for Tetraphase Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tetraphase Pharmaceuticals E10 Chart

Tetraphase Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -41.17

Tetraphase Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -41.17 -

Competitive Comparison of Tetraphase Pharmaceuticals's E10

For the Biotechnology subindustry, Tetraphase Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tetraphase Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tetraphase Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Tetraphase Pharmaceuticals's Shiller PE Ratio falls into.



Tetraphase Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tetraphase Pharmaceuticals's adjusted earnings per share data for the fiscal year that ended in Dec. 2019 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2019 (Change)*Current CPI (Dec. 2019)
=-22.85/108.4201*108.4201
=-22.850

Current CPI (Dec. 2019) = 108.4201.

Tetraphase Pharmaceuticals Annual Data

per_share_eps CPI Adj_EPS
201012 -38.221 92.474 -44.812
201112 -47.156 95.213 -53.697
201212 -15.187 96.871 -16.998
201312 -35.600 98.326 -39.255
201412 -49.800 99.070 -54.500
201512 -47.200 99.792 -51.281
201612 -42.200 101.863 -44.917
201712 -52.600 104.011 -54.830
201812 -27.480 105.998 -28.108
201912 -22.850 108.420 -22.850

Add all the adjusted EPS together and divide 10 will get our e10.


Tetraphase Pharmaceuticals  (NAS:TTPH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Tetraphase Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Tetraphase Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Tetraphase Pharmaceuticals Inc is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant, or MDR, bacteria. The company has developed its product, Xerava (eravacycline), a fully synthetic fluorocycline, as an intravenous, or IV antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections, or cIAI.
Executives
Guy Macdonald director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Larry G. Edwards director, officer: See Remarks C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
L Patrick Gage director C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Geraldine Henwood director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jeffrey Chodakewitz director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Kamalam Unninayar officer: Chief Financial Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Patrick Taylor Horn officer: Chief Medical Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David Charles Lubner officer: SVP and CFO C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Headlines

From GuruFocus

Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals

By Business Wire Business Wire 06-04-2020